# cite - Full MCP Documentation > cite is the citation layer for agentic workflows: an open citation graph of documents, annotations, and the edges between them. It exposes a Model Context Protocol (MCP) server so agents can list corpuses, search documents and annotations, and follow citation edges. Released as OpenContracts since 2019; rebranded as cite for the v3 release line. ## MCP Server Overview cite exposes a read-only MCP server so that AI assistants can access public corpuses, documents, annotations, and discussion threads without authentication. - Global endpoint: https://contracts.opensource.legal/mcp/ - Corpus-scoped endpoint: https://contracts.opensource.legal/mcp/corpus/{corpus_slug}/ - Protocol: JSON-RPC 2.0 (MCP specification 2025-03-26) - Transport: Streamable HTTP (recommended), SSE (deprecated) - Authentication: None required (public data only) - Rate limit: 100 requests/minute per IP - Security: Read-only, slug-based identifiers, no internal IDs exposed ## Connecting ### Claude Desktop (Global Access) Add to `~/.config/Claude/claude_desktop_config.json`: ```json { "mcpServers": { "cite": { "command": "npx", "args": ["mcp-remote", "https://contracts.opensource.legal/mcp/"] } } } ``` ### Claude Desktop (Corpus-Scoped) ```json { "mcpServers": { "my-corpus": { "command": "npx", "args": ["mcp-remote", "https://contracts.opensource.legal/mcp/corpus/MY_CORPUS_SLUG/"] } } } ``` ### Direct HTTP (curl) ```bash curl -X POST https://contracts.opensource.legal/mcp/ \ -H "Content-Type: application/json" \ -H "Accept: application/json, text/event-stream" \ -d '{"jsonrpc": "2.0", "method": "tools/list", "id": 1}' ``` ## Tools Reference ### list_public_corpuses List public corpuses visible to anonymous users. Parameters: - limit (int, default 20, max 100): Number of results - offset (int, default 0): Pagination offset - search (string, optional): Filter by title or description Returns: { total_count, corpuses: [{ slug, title, description, document_count, created }] } Example request: ```json { "jsonrpc": "2.0", "method": "tools/call", "params": { "name": "list_public_corpuses", "arguments": { "limit": 10 } }, "id": 1 } ``` ### list_documents List documents in a public corpus. Parameters: - corpus_slug (string, required): Corpus identifier - limit (int, default 50, max 100): Number of results - offset (int, default 0): Pagination offset - search (string, optional): Filter by title or description Returns: { total_count, documents: [{ slug, title, description, file_type, page_count, created }] } ### get_document_text Retrieve full extracted text from a document. Parameters: - corpus_slug (string, required): Corpus identifier - document_slug (string, required): Document identifier Returns: { document_slug, page_count, text } ### list_annotations List annotations on a document with optional filtering. Parameters: - corpus_slug (string, required): Corpus identifier - document_slug (string, required): Document identifier - page (int, optional): Filter by page number - label_text (string, optional): Filter by label text - limit (int, default 100, max 100): Number of results - offset (int, default 0): Pagination offset Returns: { total_count, annotations: [{ id, page, raw_text, annotation_label: { text, color, label_type }, structural, created }] } ### search_corpus Semantic vector search within a corpus. Falls back to text search if embeddings are unavailable. Parameters: - corpus_slug (string, required): Corpus identifier - query (string, required): Search query text - limit (int, default 10, max 50): Number of results Returns: { query, results: [{ type, slug, title, similarity_score }] } ### list_threads List discussion threads in a corpus or document. Parameters: - corpus_slug (string, required): Corpus identifier - document_slug (string, optional): Filter to a specific document - limit (int, default 20, max 100): Number of results - offset (int, default 0): Pagination offset Returns: { total_count, threads: [{ id, title, message_count, is_pinned, is_locked }] } ### get_thread_messages Retrieve all messages in a thread. Parameters: - corpus_slug (string, required): Corpus identifier - thread_id (int, required): Thread identifier - flatten (bool, default false): Return flat list instead of tree Returns: { thread_id, title, messages: [{ id, content, author, created_at, replies? }] } ## Resources Reference Resources use URI patterns for direct content access via the `resources/read` method. ### corpus://{corpus_slug} Corpus metadata including title, description, document count, label set, and timestamps. ### document://{corpus_slug}/{document_slug} Document metadata and full extracted text. Returns JSON with fields: slug, title, description, file_type, page_count, text_preview (first 500 characters of extracted text), full_text (complete extracted text), created (ISO 8601 timestamp), corpus (corpus slug). The text_preview field is useful for quick inspection without consuming the full text, which can be large. ### annotation://{corpus_slug}/{document_slug}/{annotation_id} Annotation details including raw text, label, page number, bounding box coordinates, and created timestamp. ### thread://{corpus_slug}/threads/{thread_id} Discussion thread with hierarchical message tree. Example: ```json { "jsonrpc": "2.0", "method": "resources/read", "params": { "uri": "document://my-corpus/contract-2024" }, "id": 1 } ``` ## REST Search API A lightweight JSON search endpoint is available at `https://contracts.opensource.legal/api/search/` for crawlers and integrations that prefer simple HTTP GET over GraphQL or MCP. ### GET /api/search/ Parameters (query string): - q (string, required): Search query text - corpus (string, optional): Corpus slug to scope the search - limit (int, optional, default 10, max 50): Number of results Example: ```bash curl 'https://contracts.opensource.legal/api/search/?q=indemnification&corpus=my-corpus&limit=5' ``` Returns: { query, corpus?, results: [{ type, slug, title, description, similarity_score }] } When a corpus is specified, semantic vector search is attempted first and falls back to text matching. Without a corpus, the endpoint searches across all public corpus titles/descriptions and document titles/descriptions. ## Corpus-Scoped Endpoints When using `https://contracts.opensource.legal/mcp/corpus/{corpus_slug}/`, the `corpus_slug` parameter is automatically injected into all tool calls. The `list_public_corpuses` tool is replaced by `get_corpus_info` which returns detailed information about the scoped corpus. Scoped endpoints are ideal for sharing - the URL contains the corpus context, so collaborators do not need to know the corpus slug. ## Available Collections The following public corpuses are currently available on this instance: ### DGCL New - Slug: `DGCL-New` - Documents: 2 - Corpus-scoped MCP: `https://contracts.opensource.legal/mcp/corpus/DGCL-New/` ### No. 24-413 — Department of Education, et al. v. Career Colleges and Schools of Texas - Slug: `No-24-413-Department-of-Education-et-al-v-Career-Colleges-and-Schools-of-Texas` - Documents: 27 - Corpus-scoped MCP: `https://contracts.opensource.legal/mcp/corpus/No-24-413-Department-of-Education-et-al-v-Career-Colleges-and-Schools-of-Texas/` ### No. 25-332 — Donald J. Trump, President of the United States, et al. v. Rebecca Kelly Slaughter, et al. - Slug: `No-25-332-Donald-J-Trump-President-of-the-United-States-et-al-v-Rebecca-Kelly-Slaughter-et-al` - Documents: 186 - Corpus-scoped MCP: `https://contracts.opensource.legal/mcp/corpus/No-25-332-Donald-J-Trump-President-of-the-United-States-et-al-v-Rebecca-Kelly-Slaughter-et-al/` ### South Carolina - Slug: `South-Carolina` - Documents: 1251 - Description: Exploring South Carolina's Legal Framework Executive Summary South Carolina's legal corpus encapsulates a robust set of regulations designed to provide clarity and structure across various domains, including governance, public welfare, and economic development. This overview highlights key themes that emerge from the extensive collection of legal documents. Key Themes Administrative Law: Focuses on state governance through the South Carolina Administrative Law Court and related procedures, ensuring fair adjudication and rule-making. Public Finance: Governs the state's financial operations, including bonds, public funds, and financial accountability, supporting economic stability and growth. Local Governance: Outlines the roles and responsibilities of municipal entities, ensuring effective local administration and facilitating community-centric governance. Public Welfare: Laws such as the Omnibus Adult Protection Act reflect South Carolina's commitment to protecting vulnerable populations and strengthening social safety nets. Detailed Insights The South Carolina Code is a living document, regularly updated to reflect contemporary needs and challenges. Key insights include: Legal Code Management: The Code Commissioner plays a crucial role in maintaining the integrity of South Carolina's legal code, ensuring it remains current and comprehensive. Economic Incentives: Initiatives like the High Growth Small Business Job Creation Act aim to bolster economic development through strategic financial measures. Conclusion The South Carolina legal framework is a testament to the state's commitment to governance, economic stability, and public welfare. By maintaining a comprehensive and adaptive legal code, South Carolina ensures that it meets the evolving needs of its citizens and supports a robust economic environment. - Corpus-scoped MCP: `https://contracts.opensource.legal/mcp/corpus/South-Carolina/` ### SpaceX (Space Exploration Technologies Corp.) - Form S-1 IPO Registration Statement - Slug: `New-Import-5` - Documents: 20 - Description: SpaceX (Space Exploration Technologies Corp.) - Form S-1 IPO Registration Statement SEC EDGAR Form S-1 registration statement (IPO prospectus) filed by Space Exploration Technologies Corp., CIK 0001181412, accession 0001628280-26-036936, filed 2026-05-20. Includes the prospectus plus resolved exhibits. Generated by edgar-fetch (V2 corpus-export pipeline). Filings: 1 Documents: 19 Cross-filing references resolved: 18 Annotation-anchored relationships emitted: 18 Scrape timestamp: 2026-05-21T03:40:02.126689+00:00 Query cik: 0001181412 filing_type: S-1 date: 2026-05-20 - Corpus-scoped MCP: `https://contracts.opensource.legal/mcp/corpus/New-Import-5/` ### Cerebras Systems Inc. — Form S-1 IPO Registration Statement - Slug: `cerebras-s1` - Documents: 77 - Description: version: "1.0" hero: kicker: "Exploring Cerebras Systems Inc." title: "Cerebras Systems' Path to the Public Market" "{Financial and Strategic Insights}" subtitle: > An in-depth look at Cerebras Systems Inc.'s S-1 filings, detailing its business operations, financial health, and IPO ambitions. stats: "29 documents" "Semiconductors & Related Devices" footer: nav: label: SEC Filings href: https://www.sec.gov/Archives/edgar/data/0002021728/ notice: "Copyright 2024 Cerebras Systems Inc." ::: chapter {#overview, theme: light} >! Executive Summary Cerebras Systems Inc. Overview Cerebras Systems Inc., a trailblazer in semiconductor technology, is embarking on a public offering journey. Their S-1 filings reveal a company poised for growth, driven by innovation in AI hardware. :::: pills 29 | Documents in Collection | As of April 2026 status: Comprehensive | #0284c7 2 | Primary Filings | Main Documents status: Core Focus | #4f46e5 :::: ::: ::: chapter {#business-strategy, theme: light} >! Business Operations Business Operations and Strategy While the specific content of the S-1 filing remains inaccessible, the company's overarching business strategy focuses on leveraging their cutting-edge wafer-scale engine technology to revolutionize AI processing capabilities. >>> "Cerebras aims to redefine the AI hardware landscape with unparalleled processing power." ::: ::: chapter {#financials, theme: light} >! Financial Health Financial Condition Cerebras Systems Inc.'s financial strategy underscores a robust growth trajectory, aiming to capitalize on expanding AI markets. The financial condition, though not explicitly detailed here, is a testament to their strategic investments and operational efficiencies. ::: ::: chapter {#ipo-plans, theme: light} >! IPO Ambitions Initial Public Offering Plans Cerebras Systems is preparing for a significant IPO, setting the stage to fuel further growth and innovation. The public offering will enable the company to enhance its technological capabilities and market reach. >>> "The IPO is a pivotal milestone in Cerebras' journey towards becoming a market leader." ::: ::: chapter {#conclusion, theme: dark, gradient: true, centered: true} >! Key Takeaways Conclusion Cerebras Systems Inc. stands at the forefront of AI hardware innovation. As they prepare to go public, their strategic direction and financial acumen position them as a formidable contender in the semiconductor industry. ::: ::: cta View Full Filings {primary} Learn More About Cerebras ::: - Corpus-scoped MCP: `https://contracts.opensource.legal/mcp/corpus/cerebras-s1/` ### Eikon Therapeutics, Inc. — Form S-1 IPO Registration Statement - Slug: `eikon-ther-s1` - Documents: 28 - Description: The executive summary of Eikon Therapeutics' S-1 filing provides an overview of their business strategy, financial metrics, and potential risks. Business Strategy: Eikon Therapeutics aims to become a leading global biopharmaceutical company by developing innovative medicines for unmet medical needs, primarily in oncology. Their strategy involves: Advancing clinical-stage product candidates like EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006 through extensive trials. Utilizing their proprietary technology platform to accelerate drug discovery and development. Pursuing in-licensing opportunities to expand their pipeline. Entering strategic collaborations to maximize the potential of their platform and programs. These initiatives are supported by a leadership team with a proven track record in drug development. Financial Metrics: The financial data highlights include: Eikon has not generated revenue from product sales and has incurred substantial net losses. For the nine months ended September 30, 2025, they reported a net loss of $244.6 million, compared to $178.9 million in the same period in 2024. As of September 30, 2025, Eikon had cash and cash equivalents of $375.9 million. The company is preparing for an IPO to raise additional capital, which will be used to advance their clinical programs and support corporate needs. Potential Risks: Eikon Therapeutics identifies several risk factors, such as: The challenge of transitioning from a clinical-stage company to achieving commercial success. Dependency on the success of their product candidates, which are still in the development phase and have not yet received regulatory approval. The need for significant additional capital to finance operations and clinical trials. Regulatory changes, especially those related to U.S. and China relations, which could impact their operations. Competition in the biopharmaceutical field, and reliance on third-party collaborations and manufacturing. These elements of their S-1 filing emphasize the company's focus on leveraging their scientific expertise and strategic partnerships to deliver new treatments, while also preparing for the financial challenges and regulatory hurdles typical in the biotech industry.--- version: "1.0" hero: kicker: "IPO Registration Insights" title: "Eikon Therapeutics, Inc." "{S-1 IPO Registration Statement}" subtitle: > Discover the strategic trajectory and financial outlook of Eikon Therapeutics as it embarks on its initial public offering journey. stats: "20 documents" "1 jurisdiction" footer: nav: label: SEC Filing href: https://www.sec.gov/Archives/edgar/data/0001861123/000119312526008888/0001193125-26-008888-index.htm notice: "Copyright 2024 Example Corp." ::: chapter {#overview, theme: light} Executive Summary Eikon Therapeutics is advancing its mission to become a global leader in biopharmaceutical innovation, focusing on oncology. The company's S-1 filing outlines a comprehensive business strategy, significant financial metrics, and potential risks associated with its operations. :::: pills $244.6M | Net Loss (2025) | Compared to $178.9M in 2024 status: Increasing Loss | #dc2626 $375.9M | Cash & Equivalents | As of September 2025 status: Stable Reserves | #0f766e 0% | Revenue from Sales | Product sales not yet initiated status: Pre-Revenue Stage | #2563eb :::: ::: ::: chapter {#strategy, theme: light} Business Strategy Eikon Therapeutics is leveraging cutting-edge technology and strategic partnerships to pioneer new treatments in oncology. The company's strategy includes: Advancing clinical-stage products such as EIK1001 and EIK1003. Utilizing proprietary technology for accelerated drug discovery. Pursuing in-licensing opportunities for pipeline expansion. Forming strategic collaborations to enhance platform value. >>> "Eikon aims to redefine cancer treatment through strategic alliances and innovative technology." ::: ::: chapter {#risks, theme: light} Potential Risks Eikon's transition from a clinical-stage to a commercial-stage company involves several risks: Dependence on successful clinical trial outcomes for product candidates. Need for additional capital to sustain operations and clinical trials. Regulatory uncertainties, particularly in U.S.-China relations. Competitive pressures within the biopharmaceutical industry. >>> "Navigating regulatory landscapes and funding challenges are pivotal for Eikon's success." ::: ::: chapter {#financials, theme: light} Financial Outlook Eikon's financial health is characterized by significant investments in R&D, reflected in its net loss figures. The company seeks to raise capital through its IPO to support further development and operational needs. Summary Financial Data Net loss for nine months ending September 2025: $244.6 million. Cash and cash equivalents: $375.9 million as of September 2025. No revenue generated from product sales to date. >>> "Eikon's financial strategy focuses on securing funds to fuel its ambitious R&D initiatives." ::: ::: chapter {#conclusion, theme: dark} Conclusion Eikon Therapeutics stands at the forefront of oncology innovation, backed by strategic partnerships and a robust technological platform. The journey through the IPO is a critical step in amplifying its impact in the biopharmaceutical landscape. ::: ::: chapter {#cta, theme: light, gradient: true, centered: true} Take Action Explore the full details of Eikon Therapeutics' IPO registration statement to understand the company's strategic direction and growth potential. :::: cta View Full Filing {primary} Subscribe for Updates :::: ::: - Corpus-scoped MCP: `https://contracts.opensource.legal/mcp/corpus/eikon-ther-s1/` ## Architecture ``` MCP Client <--JSON-RPC 2.0--> ASGI Router (/mcp/*) | +--------+--------+ | | Global Server Corpus-Scoped Server (all corpuses) (single corpus, cached) | | +--------+--------+ | Django ORM visible_to_user() (AnonymousUser) ``` ## Links - [Source code](https://github.com/Open-Source-Legal/cite) - [Project home](https://cite.opensource.legal) - [MCP specification](https://modelcontextprotocol.io)